ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (EHA)

For more information about this resource, please submit a medical information request.

Presented at the 25th Congress of the European Hematology Association (EHA25 Virtual), June 11-14, 2020

Abstract: S225